Investment
Features
FeesSafety
Academy
More
Pluang+

Stillwater reports strong rhodium and chromium results at Stillwater West, Montana, boosting US critical minerals supply.

Market News
21 May 2026
Accesswire
View Source
Bullish
Stillwater reports strong rhodium and chromium results at Stillwater West, Montana, boosting US critical minerals supply.

Stillwater Critical Minerals announced positive rhodium assay results from its 2025 drilling campaign at the Stillwater West project in Montana, confirming widespread rhodium mineralization alongside chromium and other critical minerals. The project hosts the only known rhodium resource in the US, with rhodium prices around $10,000/oz, and a significant chromium resource of 2.3 billion pounds, vital for steel production and defense. These findings support the polymetallic nature of the deposit and will be included in an updated Mineral Resource Estimate expected in the first half of 2026. The company is advancing the project as a key domestic source of multiple critical minerals important for industrial, energy, and defense sectors in the US.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
56 minutes ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
1 hour ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
2 hours ago
NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

BNP Paribas Exane raised NVIDIA's price target from $285 to $345 due to strong demand for its AI chips, signaling potential upside of about 45.6% from the current price. NVIDIA shares have gained about 25% in 2026, driven by growth in AI infrastructu...

Analyst Insights
Bullish
3 hours ago
Bitcoin hits predicted peak of $126K on Oct 6, 2025; next bottom forecasted for Oct 5, 2026 near $86K.

Bitcoin hits predicted peak of $126K on Oct 6, 2025; next bottom forecasted for Oct 5, 2026 near $86K.

A 4chan post from December 2023 accurately predicted Bitcoin's all-time high of around $126,000 on October 6, 2025, based on a 364-day market cycle pattern. Following the peak, Bitcoin dropped about 52% by mid-2026 but has since recovered to roughly ...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App